"Amyloid beta-Peptides" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Peptides generated from AMYLOID BETA-PEPTIDES PRECURSOR. An amyloid fibrillar form of these peptides is the major component of amyloid plaques found in individuals with Alzheimer's disease and in aged individuals with trisomy 21 (DOWN SYNDROME). The peptide is found predominantly in the nervous system, but there have been reports of its presence in non-neural tissue.
| Descriptor ID |
D016229
|
| MeSH Number(s) |
D12.644.024 D12.776.049.407.249.500 D12.776.543.039.500
|
| Concept/Terms |
Amyloid beta-Peptides- Amyloid beta-Peptides
- Amyloid beta Peptides
- beta-Peptides, Amyloid
- Alzheimer's ABP
- ABP, Alzheimer's
- Alzheimer ABP
- Alzheimers ABP
- Alzheimer's Amyloid Fibril Protein
- Amyloid AD-AP
- AD-AP, Amyloid
- Amyloid AD AP
- beta-Amyloid Protein
- Protein, beta-Amyloid
- beta Amyloid Protein
- Amyloid beta-Protein
- Amyloid beta Protein
- beta-Protein, Amyloid
- Amyloid beta-Proteins
- Amyloid beta Proteins
- beta-Proteins, Amyloid
- Amyloid Fibril Protein, Alzheimer's
- Amyloid Protein A4
- Protein A4, Amyloid
- Alzheimer beta-Protein
- Alzheimer beta Protein
- beta-Protein, Alzheimer
- Amyloid beta-Peptide
- Amyloid beta Peptide
- beta-Peptide, Amyloid
|
Below are MeSH descriptors whose meaning is more general than "Amyloid beta-Peptides".
Below are MeSH descriptors whose meaning is more specific than "Amyloid beta-Peptides".
This graph shows the total number of publications written about "Amyloid beta-Peptides" by people in this website by year, and whether "Amyloid beta-Peptides" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 1 | 0 | 1 |
| 1999 | 2 | 0 | 2 |
| 2000 | 1 | 1 | 2 |
| 2001 | 1 | 1 | 2 |
| 2002 | 2 | 1 | 3 |
| 2003 | 5 | 1 | 6 |
| 2004 | 2 | 0 | 2 |
| 2005 | 4 | 1 | 5 |
| 2006 | 3 | 2 | 5 |
| 2007 | 1 | 5 | 6 |
| 2008 | 0 | 2 | 2 |
| 2009 | 4 | 3 | 7 |
| 2010 | 3 | 3 | 6 |
| 2011 | 7 | 4 | 11 |
| 2012 | 4 | 0 | 4 |
| 2013 | 1 | 6 | 7 |
| 2014 | 4 | 5 | 9 |
| 2015 | 3 | 2 | 5 |
| 2016 | 2 | 2 | 4 |
| 2017 | 4 | 2 | 6 |
| 2018 | 6 | 2 | 8 |
| 2019 | 4 | 4 | 8 |
| 2020 | 3 | 4 | 7 |
| 2021 | 6 | 6 | 12 |
| 2022 | 0 | 5 | 5 |
| 2023 | 0 | 5 | 5 |
| 2024 | 1 | 6 | 7 |
| 2025 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Amyloid beta-Peptides" by people in Profiles.
-
Amyloid-Related Imaging Abnormalities (ARIA) in Clinical Trials of Gantenerumab in Early Alzheimer Disease. JAMA Neurol. 2025 Jan 01; 82(1):19-29.
-
Long-term safety of gantenerumab in participants with Alzheimer's disease: A phase III, open-label extension study (SCarlet RoAD). J Alzheimers Dis. 2025 Jan; 103(2):528-541.
-
The POINTER Imaging baseline cohort: Associations between multimodal neuroimaging biomarkers, cardiovascular health, and cognition. Alzheimers Dement. 2025 Jan; 21(1):e14399.
-
Clinical progress note: Anti-amyloid monoclonal antibodies. J Hosp Med. 2024 Oct; 19(10):934-937.
-
Multitarget action of Benzothiazole-piperazine small hybrid molecule against Alzheimer's disease: In silico, In vitro, and In vivo investigation. Biomed Pharmacother. 2024 May; 174:116484.
-
Nonalcoholic Fatty Liver Disease and Longitudinal Change in Imaging and Plasma Biomarkers of Alzheimer Disease and Vascular Pathology. Neurology. 2024 Apr 09; 102(7):e209203.
-
Study Partner Report of Apathy in Older Adults is Associated with AD Biomarkers: Findings from the Harvard Aging Brain Study. Am J Geriatr Psychiatry. 2024 08; 32(8):909-919.
-
Research Participants' Perspectives on Precision Diagnostics for Alzheimer's Disease. J Alzheimers Dis. 2024; 97(3):1261-1274.
-
At-Home Administration of Gantenerumab by Care Partners to People with Early Alzheimer's Disease: Feasibility, Safety and Pharmacodynamic Impact. J Prev Alzheimers Dis. 2024; 11(3):537-548.
-
Two Phase 3 Trials of Gantenerumab in Early Alzheimer's Disease. N Engl J Med. 2023 Nov 16; 389(20):1862-1876.